Downregulation of BBOX1-AS1 increases sorafenib sensitivity in patient-derived organoid models
(A) Cell viability and IC50 were assessed for all six HCC patient organoids. (B) Representative light field images of sorafenib-treated HCC organoids (patients 2 and 5). Scale bar: 500 μm. (C) Light field images of organoids from patient 5 (days 0 and 4) with indicated treatment. (sorafenib: 8 μM). Scale bar: 500 μm. (D) Organoid size change of organoids with indicated treatment (relative to the beginning for each treatment). (E) Cell viability of organoids with indicated treatment on day 4. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.